Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer

BACKGROUND: Canfosfamide is a novel glutathione analog activated by glutathione S-transferase P1-1. This study evaluated the safety and efficacy of canfosfamide in combination with pegylated liposomal doxorubicin (PLD) in patients with platinum resistant ovarian cancer. Patients with platinum resist...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Kavanagh, John J, Levenback, Charles F, Ramirez, Pedro T, Wolf, Judith L, Moore, Carla L, Jones, Marsha R, Meng, Lisa, Brown, Gail L, Bast, Robert C
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2010
Témata:
Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2851575/
https://ncbi.nlm.nih.gov/pubmed/20222977
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-8722-3-9
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky